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The provision of immunotherapy through anti body infusion has a venerable and valuable record in the treatment of infectious disease. In 1901, the first Nobel Prize in Physiology or Medicine was awarded to Emil von Behring for "serum therapy, especially its application against diph theria," and more recently, postexposure prophy laxis against rabies has combined antibody treatment with active immunization. Although immunotherapy for chronic, persistent infections is more problematic, new studies by Barouch et al. 1 and Shingai et al. 2 on the treatment of rhesus macaques indicate that monoclonal anti bodies show much promise in clearing infection with a hybrid form of the simian immunodefi ciency virus (SIV) that bears the envelope antigens of the human immunodeficiency virus type 1 (HIV1) and SIV, referred to as SHIV.
During the past few years, several novel monoclonal antibodies that have been derived from cells from HIVinfected persons combine extraordinarily high potency with breadth in neu tralizing diverse strains of HIV1. The impetus for this work has come from vaccine research that is based on the premise that a better under standing of how these monoclonal antibodies bind to the HIV envelope will lead to the design of protective immunogens. This important goal has yet to be realized, but the new studies indi cate that the same monoclonal antibodies can be used therapeutically. A rapid and profound clear ance of virus from the peripheral blood of in fected macaques after the infusion of one or more monoclonal antibodies was observed by both Barouch et al. 1 and Shingai et al. 2 Although the virus eventually reappeared as levels of monoclonal antibodies waned over time, in sev eral animals viral levels did not rebound to their pretreatment level, indicating that the set point of the viral load was permanently reduced.
The exact mechanism through which mono clonal antibodies work remains to be elucidated. Their effectiveness as potent neutralizers of in fectious HIV particles has been established, but it is also thought that they may reduce the num ber of virusproducing cells. Such destruction of the factories of virus production ( Fig. 1) The answer may be a longterm effect and an alter native treatment for those in whom antiretrovi ral treatment has failed. Moreover, a combination of conventional drugs and immunotherapy may be better than either alone. One of the problems with antibody therapy is the need for repeated injections of the monoclonal antibody in order to maintain levels sufficient to control the virus. An alternative is to deliver the genes encoding the heavy and light chains of the monoclonal antibody so that the patient can generate it inter nally. Balazs et al. 4 have studied this approach. Using a mouse model containing human lym phoid tissue, they observed that the genetic de livery of a neutralizing monoclonal antibody through a viral vector blocked HIV1 infection. Moreover, a single intramuscular injection in duced lifelong expression of the monoclonal anti body at high plasma levels, suggesting that this approach could be considered for immunother apy as well as immunoprophylaxis.
Potent neutralization of antiHIV monoclonal antibodies can also prevent new infection when locally administered before a mucosal SHIV challenge. It is often assumed that mucosal im munity requires secretory IgA responses, although we know that protection against cervical cancer through human papillomavirus vaccines is main ly achieved through IgG. Watkins et al. 5 recently reported that the use of passive monoclonal anti body protection with dimeric IgA1 (which cap tures virus particles and prevents their trans cytosis across mucosal cells) was more effective than direct neutralization of SHIV, whereas the nontranscytotic dimeric IgA2 isotype of the same monoclonal antibody offered poor protection. This observation should be borne in mind if monoclonal antibodies are to be developed as vaginal microbicides for the prevention of HIV1 transmission.
Monoclonal antibodies already have a well established role in immunotherapy for cancer and autoimmune disease. There is no reason to hesitate to explore their clinical potential for use in the control of chronic infection with virus es such as HIV1, especially given the recent data on the effects of treatment with highly potent, broadly neutralizing monoclonal antibodies.
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